



August 2020 Virtual Interim Work Group Recaps:

For results of Data Element Request Forms (DERFs) and External Code List (ECLs) reviewed see DERF Resolution at <https://member.ncpdp.org/work-groups.aspx?ID=wgmc>.

Work Group 1 Telecommunication

DERFs/ECLs Reviewed:

- DERF 001753/ECL 000321 was recommended to MC to pend.
- DERF 001768/ECL 000326 was recommended to MC to approve.
- DERF 001769/ECL 000327 was recommended to MC to approve.
- DERF 001770/ECL 000328 was recommended to MC to approve.
- DERF 001771/ECL 000329 was recommended to MC to approve as modified.
- DERF 001772/ECL 000330 was not reviewed. Refer to the MC Maintenance and Control recap.

Task Groups:

- The **Telecommunication FAQ Task Group** reviewed and approved adding three questions to the *Telecommunication Version D and Above Questions, Answers and Editorial Updates* document.
 - The **FAQ Controlled Substance Guidance Update Sub-Task Group** updated the *Recommended Use of Quantity Prescribed (460-ET) in NCPDP Telecommunication Standard Version D.0* white paper following the release of the Quantity Prescribed Final Rule. The group requested the addition of three FAQs to the *Telecommunication Version D and Above Questions, Answers and Editorial Updates* document. The group will create a new DERF with changes to the Dispensing Status to meet the needs of Controlled Substance prescriptions.
- The **Coordination of Benefits Task Group** reviewed and answered two questions. The *Dual Eligible Part B Claims Processing Barriers and Recommendations* white paper was approved. The group will begin drafting a FAQ for publication. The group will work on version transition guidance, create COB Payer Sheet guidance, review current tax guidance and develop a COB educational webinar.
- The **Information Reporting Problems Task Group** updated the N2 to N1 Matching Logic documents located on RelayHealth Nx Transaction webpage under Related Documents, requested the addition of “none” to the email subject line for Nx Reject Report emails and continued review of the *Overview of the Medicare Part D Prescription Drug Coordination of Benefits (COB) Process* white paper.
- The **Post Adjudication Task Group** did not meet the past two quarters.
- The **Definition of a Valid Prescriber Task Group** is transitioning to two new task group leads. The group assisted with the WG1 Usage of Submission Clarification Code webinar, created five new FAQs with one being published in the *NCPDP Emergency Preparedness Guidance* document. The task group will continue work on sunseting Prescriber ID qualifiers, update/remove *Telecommunication Version D and Above Questions, Answers and Editorial Updates* document FAQs regarding Medicare Part D Prescriber Enrollment, determine guidance needs for vF6 prescriber changes, review the need for a white paper and reevaluate task group goals.
- The **Eligibility Verification Enhancements Task Group** did not meet the past two quarters.
- The **Benefit Integration Task Group** continues to modify the Benefit Integration Implementation Guide to include Benefit Synchronization where appropriate. The group is looking at the schema in relation to Synchronization, specifically looking at examples for Benefit Synchronization.
- The **Standardized Subrogation Task Group** did not meet the past two quarters.

- The **Usage of Submission Clarification Codes (SCC) Task Group** developed and conducted a webinar on correct usage of Submission Clarification Codes.
- The **Compound Task Group** discussed the guidance for reporting Quantity Prescribed when one of the drugs in a compound is a CII and reviewed the Quantity Prescribed verbiage for the *Telecommunication Version D and Above Questions, Answers and Editorial Updates* document related to compounds. The group is going on hiatus for one quarter.
- The **Expand Dollar Fields Task Group** did not meet the past two quarters.
- The **Clinical and Safety Edits Task Group** continues to categorize the DUR Codes. The group is considering developing a survey on the current use of the DUR codes. The group reviewed guidance around safe disposal of medication and is drafting content to be added to the *Telecommunication Version D and Above Questions, Answers and Editorial Updates* document.
- The **Point of Sale Rebate Review Task Group** did not meet the past two quarters.
- The **Telecommunication Agility Next Generation (TANG) Task Group** agreed to support a data model approach, where the RTPB model would be used as the starting point, created a questionnaire to gather more information and reviewed the extensibility process established for XML based standards. The group will review survey results, create a recommendation for next quarter and begin working on a logical data model.
- The **Pharmacy Locator for Backordered Medications Task Group** reviewed various ideas around creating solutions to locating pharmacy products. Based on feedback from the presentation at Work Group, the task group will continue their work. The work group approved a new task group name and goals as modified.

Other Reportables:

- **DSMO Change Requests:** An update on the status of the DSMO Change Request 1201 (New Version of the Batch Standard), 1202 (New Standard - Subrogation Implementation Guide for Batch Standard) and 1208 (New Version of the Telecommunication Standard) was provided in the WG1 download materials.
- **WG16 Workers' Compensation Monitoring, Billing and Education Task Group, MC RTPB Standard Task Group, WG11 X12 270/271 Version 7030 Review Task Group and WG11 REMS Workflow to Transactions Task Group:** Recaps for these task groups were provided in the WG1 download materials.

New Business:

- **WG1 Scope and Goals** were reviewed and approved as modified.
- The WG16 P and C/WC Monitoring, Billing and Education Task Group transitioned to WG1.

Work Group 2 Product Identification

DERF Reviewed:

- DERF 001773 was approved.

Task Groups:

- The **Product Review and Billing Unit Exception Task Group** reviewed issues resulting from changes to existing products or to the release of new products. The task group:
 - Reviewed and submitted to WG2 for adjudication two new QUIC forms (see final adjudication determination by the Work Group in this report):
 - QUIC #202003 Lurbinectedin
 - QUIC #202005 JELMYTO (*on hold*)
 - Reviewed, updated and edited the Billing Unit Standard Implementation Guide as part of ANSI requirement to ballot every five years. DERF 001773 Billing Unit Standard Implementation Guide Version 4.0 was approved.

- Reviewed ten products via email and four during task group calls for verification of either the package size and billing unit or the product identifier to list within the drug data compendia files.
- Determined the billing unit and package size assignment for COVID-19 tests.
- Created the COVID-19 Test Specimen Collection Product Identifier for the use case of the pharmacy staff observing the specimen collection process and the sample is sent to a lab.
- Sent a letter to three insulin pen manufacturers and the FDA expressing concerns about FDA guidance to dispense insulin pen products in the original sealed carton. The letters also requested consideration of adding single unit packaging for insulin pen products.
- Sent letters to two manufacturers who changed their package size but not the NDC on their product.
- For January through June 2020, 4,402 new SPL Billing Unit Index files were generated with no changed SPL Billing Unit Index files based on the files received by the FDA from the compendia. The compendia group has reconciled the 23 of the 24 NDCs with discrepancies.
- The **Naming Standards for Drugs, Biologics and Biosimilars Task Group** drafted and submitted three letters/written comments to:
 - Lubna Merchant of the FDA requesting clarification of naming standards to be applied to fixed-combination biologics.
 - The Joint FDA and FTC Workshop on Competitive Marketplace for Biosimilars.
 - The United States Pharmacopeia USP regarding biologics naming in the revision to Section 2.20 Official Articles of the General Notices and Requirements

The task group also drafted a survey to determine the impact of FDA's biologics naming practice.

- The **Application of the Billing Unit Standard Clarification Task Group** agreed to an alternative to a stand-alone document to provide the rationale used to determine the billing unit from past QUIC forms/products reviewed. The Billing Unit Standard was modified to cite the QUIC forms and/or DERFs in the publication history. This modification was incorporated with DERF 001773. Since their work is complete, the task group requested to disband, and the Work Group approved.
- The **Outsourcing Facility Task Group** did not meet the last two quarters. The letter requesting the addition of a new Structured Product Labeling (SPL) Marketing Category for Outsourcing Facility (OSF) Medications was sent to the FDA on March 10, 2020. The FDA sent a response stating the request was unclear. The task group will determine next steps.

Other Reportables:

- **WG11 REMS Workflow to Transaction Task Group, MC NDC Scarcity Task Group and MC Digital Therapeutics Task Group:** Recaps for these task groups were provided in the WG2 download materials.

New Business:

- New QUIC Form Review and Final Adjudication:
 - QUIC #202003 Lurbinectedin
BU=EA and Quantity of 1 for a single vial per section 5.1.2 of the Billing Unit Standard.
- The revised **WG2 Scope and Goals** were reviewed and approved.
- There was a request to the work group members to submit any concerns regarding current product labeling which is placing any stakeholder (e.g., pharmacy, processor, patient) at risk. NCPDP will compile these examples for a future meeting with the FDA.

Work Group 7 Manufacturer and Associated Trading Partner Transaction Standards

Task Groups:

- The **Manufacturer Rebate Standard Task Group** reviewed the white paper, *Challenges and Opportunities for Stakeholders Regarding ePrescribing Technologies and Formulary Compliance*, which was developed jointly by WG7 and WG11 ePrescribing and Related Transactions and published in 2013. The white paper is outdated and has been removed from the NCPDP website. Discussion continues on whether to update the white paper. The task group is discussing potential modifications to the Manufacturer Rebate Standard to better accommodate practical use of transmitting formulary and benefit information. Fields designated as primary “cross-linking” fields to the formulary and benefit files are not actually used in current practice. The task group will also analyze the results of the industry survey and determine next steps.
 - The **Manufacturer Rebate Standard Medicaid Reporting Sub-Task Group** did not meet the past two quarters.
- The **Medical Rebate Standard Task Group** did not meet the past two quarters.

New Business:

- **WG7 Scope and Goals** were reviewed and approved as modified.

Work Group 9 Government Programs

Ballot Adjudication:

- **Ballot WG090015** – Enhancements to the Prescription Drug Monitoring Programs (PDMP) Reporting Standard Implementation Guide Version 13 is considered a valid ballot having received the required 60+% of Consensus Group votes and 75%+ approval rating. See Letter Ballot Comment spreadsheet for the ballot results and categorization of comments on the WG9 webpage. The ballot will be sent to NCPDP Board of Trustees for approval after a 30-day appeal period.

DERFs/ECLs Reviewed:

- DERF 001774/ECL 000331 was recommended for MC to deny.
- DERF 001775/ECL 000332 was recommended for MC to approve.

Task Groups:

- The **Prescription Drug Monitoring Program (PDMP) Task Group** completed the white paper, *NCPDP’s Standards-based Facilitator(s) Model for PDMP, An Interoperable Framework for Patient Safety, Phase I and Phase II*, which was approved by WG9. The task group also monitored PMP information for California, Florida, Illinois, Kentucky, Maine, Nebraska, New Jersey, Oklahoma, Pennsylvania, Rhode Island, Utah and Washington and updated the [State PMP Tracking Document](#) which was approved by WG9.
- The **340B Task Group** reviewed the definition of 340B used in Submission Clarification Code (420-DK) and Submission Type Code (D17-K8) and submitted DERF 001774/ECL 000331 requesting a modification to the definition. Next quarter the task group will continue to review comments received on version 2.0 of the *340B Information Exchange Reference Guide*.
- The **Government Programs Encounter Reporting Standards Task Group** continued their work on the development of one common standard that can be used by all states to report Medicaid pharmacy encounter data. The task group completed the categorization of each data element in the working document and the mandatory/situational usage of each. Next quarter the task group will develop the file layout and implementation guide.
- The **Medicaid Frequently Asked Questions Task Group** reviewed the state of New York’s COVID-19 guidance regarding the use of Submission Clarification Code (420-DK) value 07 (Medically Necessary) rather than value 13 (Payer-Recognized Emergency/Disaster Assistance Request). The task group wrote a letter to the State Medicaid Directors regarding the use of the Quantity Prescribed field (460-ET). The task group reviewed an inquiry related to the implementation of electronic Prior

Authorization by state Medicaid programs considering the delay of the Part D rule. The task group also reviewed an inquiry regarding “CMS Guidance: Reporting Dispensing Fee in the T-MSIS Claim RX File” which appears to contradict the Telecommunication Standard vD.0 Prescription Response Formula, specifically the Patient Pay Amount (505-F5) field.

- The **Medicaid Formulary Standard File Layout Sub-Task Group** was disbanded.
- The **Hospice Task Group** participated in the development of a recommendation from the Medicare Part D Transaction Facilitator and CMS to create a file/transaction process allowing real-time hospice eligibility to Part D plan sponsors/PBM’s. The task group also submitted comments on CMS-1733-P Medicare Program; FY 2021 Hospice Wage Index and Payment Rate Update, specifically the election statement and addendum.
- The **Medicare Standardized Fraud, Waste and Abuse (FWA) Training Attestation Task Group** did not meet the past two quarters.
- The **Medicare Prescription Drug Event (PDE) Task Group** reviewed eleven questions this quarter (Q49, Q75, Q80, Q81, Q82, Q83, Q84, Q85, Q86, Q87, Q88). Six questions were submitted to CMS. The task group responded to an inquiry from WG1 Telecommunication FAQ Task Group regarding Quantity Prescribed and Compounds and reviewed CMS memo dated May 22, 2020 related to COVID-19.
- The **Medicare Financial Information Reporting (FIR) Task Group** provided input on changes to the Daily Cumulative FIR Aging Report.
- The **Medicare Part D FAQ Task Group** reviewed FAQ 161 from CMS regarding the processing of Part D transactions for patients with a Worker’s Compensation injury (Worker’s Compensation Medicare Set Aside (WCMSA)) and after coordination with **WG16 P&C/WC Monitoring, Billing and Education Task Group** submitted recommendations to CMS. The task group also submitted DERF 001775/ECL 000332 requesting a new reject code for WCMSA which was approved by WG9. Other topics reviewed by the task group include Gender Codes and CMS Eligibility/PDE, Notice of Appeal Rights, Fill Number, Daily Cost Share, Quantity Prescribed and Compounds and EOB Price Change.
- The **Coordination of Benefits Contractor (COBC)/Benefits Coordination & Recovery Center (BCRC) Task Group** reviewed the following topics: Matching COB-OHI to Medicare Part D Eligibility, Pharmaceutical Assistance Programs issues/questions, Incorrect Section 111 primary reporting on COB records, Supplemental benefit reported as primary coverage, Non-network drug records, COB-OHI History, Reject for effective date of other drug coverage, BCRC clean-up of Invalid BINs, COB-OHI records with blank insurer name, prevention of incorrect primary COB-OHI records. During the next quarter, the task group will continue to work on the COB-OHI industry issues list.
- The **Medicare Part D Multi-Payer Reconciliation Task Group** did not meet the past two quarters.

New Business:

- **WG9 Scope and Goals** were reviewed and approved as modified.

Work Group 10 Professional Pharmacy Services

Old Business:

- Guest Speaker: RADM (Retired) Pamela Schweitzer – Pay to Payment for Pharmacy Services.
 - The presentation covered pharmacy profession efforts underway related to scope of practice, reimbursement for professional services along with legislative and regulatory changes.

Task Groups:

- The **Electronic Referral Task Group** completed examples to be included in *V2017071 SCRIPT Standard Examples Guide* once the WG110085 ballot process is completed.

- The **Identification of Social Determinants of Health Task Group** reviewed use cases and answered questions from the WG11 SIR Task Group concerning using SCRIPT transactions to send Social Determinants of Health codes. Once the recommendation is finalized, implementation recommendations for SCRIPT Version 2017071 will be addressed.
- The **MTM and Pharmacist Clinical Services Task Group** received a request from the MC Patient Identification Task Group to update the Pharmacist eCare Plan to support communication of universal patient identifiers and to ensure anytime stakeholders are communicating with each other about a patient, best practices are used to identify the patient. This process would be applicable for any type of transaction that is exchanging/requesting/transacting information about a patient. The NCPDP/HL7 Pharmacist eCare Plan C-CDA template and Fast Healthcare Interoperability Resources (FHIR®) Implementation Guides (IGs) completed balloting at HL7 and NCPDP in 2019. The HL7 FHIR® Management Group requested some clarifications. When their review is complete, it will move to the HL7 Technical Steering Committee for approval and then submission to ANSI. For the CMR Summary FHIR® wrapper, a draft Project Scope Statement to submit to HL7 to create a FHIR® Release 4 version was created. After review, the statement will be submitted to the HL7 Pharmacy Work Group. The National Institute of Health (NIH) Agency for Healthcare Research and Quality (AHRQ) is looking at a project to create a Care Summary for multiple chronic conditions which will affect a portion of the Care Summary. This project would engage the patient by seeing the Care Summary which fits with the work on the Medicare Part D side because the intent is to share with the patient. For the Beneficiary Level Report (BLR), it was recommended the task group prepare a guidance document. The task group will write a white paper recommending a BLR standard for exchange between the provider of the MTM services to the MAPD or PDP including identification of NCPDP and or HL7 standards.
- The **mL White Paper Task Group** continues to update the White Paper. Because of changes in language to the NABP Model Act and Model Rules for the Practice of Pharmacy, the National Association of Boards of Pharmacy was contacted for clarification and review of the White Paper draft. The revised version was submitted to the Standardization Committee for review and was approved after several iterations in July. The educational session originally scheduled for NCPDP's 2020 Annual Conference in May has been rescheduled as a webinar.
- The **Universal Medication Schedule White Paper Task Group** is on hiatus while NCPDP staff, Task Group leadership and members continue to engage Mike Wolf, the principal investigator and advocate for UMS, in establishing strategies for revision of the white paper.

Other Reportables:

- **WG18 Specialty Requirements for ePrescribing Task Group, WG10/WG14 Standardized Medication Profile Task Group and WG14 Consultant Pharmacist Interoperability Task Group:** Recaps for these task groups were provided in the WG10 download materials.

Work Group 11 ePrescribing & Related Transactions

- **Ballot WG110084**-enhancement to the SCRIPT, Specialized and XML Standard is considered a valid ballot having received the required 60% of Consensus Group votes. There were eight affirmative comments which were categorized as persuasive and editorial. There was one negative with reason comment which was categorized as not persuasive. The submitter of the negative with reason comment will be given the opportunity to change the vote.
 - If the negative vote is not changed, the ballot will be re-circulated.
 - If the vote is changed to Affirmative or Abstain, no ballot re-circulation is required, and an appeal period of 30 days will begin. If there are no appeals received, notification of the ballot results and the ballot documents will be sent to the Board for approval. Should the Board approve, the

Standard documents will be released with the date of Board approval.

DERFs/ECLs Reviewed:

- DERF 001755 was pended to the SCRIPT Implementation Recommendations Task Group for additional work.
- DERF 001757 was withdrawn by the submitter.
- DERF 001760 was approved as modified.
- DERF 001763 was withdrawn by the submitter.
- DERF 001776 was approved as modified.
- DERF 001777 was approved.
- DERF 001778 was approved.
- DERF 001779 was pended to the SCRIPT Implementation Recommendations Task Group for additional work.
- DERF 001780 was pended to the SCRIPT Implementation Recommendations Task Group for additional work.
- DERF 001781 was approved.
- DERF 001782 was pended back to the task group for additional work.
- DERF 001783 was approved as modified.
- DERF 001784 was approved.
- DERF 001785 was approved.
- DERF 001786 was approved.
- DERF 001787 was approved.
- DERF 001788 was approved as modified.
- DERF 001789 was approved.

Task Groups:

- The **Dispensed Medication Reporting Task Group** did not meet the past two quarters.
- The **ePrescribing Regulatory Task Group** reviewed and provided comments from NCPDP for the DEA EPCS IFR.
- The **Formulary and Benefit Task Group** submitted DERF 001782. They decided to delay requesting the *Formulary and Benefit Standard Version 53* be named in regulation until November 2020. A new task group will be created in MC Maintenance and Control to address concerns with how RTPB and F&B interact.
- The **Implementation of Structured Sig Task Group** worked with the WG11 XML Task Group on some naming and structure issues with the structured sig format.
- The **Prior Authorization Workflow to Transactions Task Group** brought forth DERF 001783. They also brought forth one FAQ which was approved for addition to the *SCRIPT Implementation Recommendations* document.
- The **REMS Workflow to Transactions Task Group** brought forth DERF 001784.
- The **WG11/WG14 RxFill Task Group** continues to work on future guidance and modifications to the RxFill message.
- The **SCRIPT Implementation Recommendations Task Group** brought forth DERFs 001776, 001777, 001778, 001779, 001780, 001781 and 001787 and received approval for new or modified FAQs and/or guidance for inclusion in the *SCRIPT Implementation Recommendations* document. One FAQ was removed from the list and sent back to the task group for additional work. The Pharmacy to Pharmacy Prescription Transfer Task Group was reinstated to look at push use cases.
 - The **Alternate Response Sub-Task Group** brought forth DERF 001755 and FAQ for inclusion in the *SCRIPT Implementation Recommendations* document.

- The **RxChange Guidance Review Sub-Task Group** brought forth a FAQ to be included in the *SCRIPT Implementation Recommendations* document. They will continue reviewing current guidance and update, as necessary.
- The **Allergy and Adverse Event Sub-Task Group** created updated guidance to add to the *SCRIPT Implementation Recommendations* document.
- The **CancelRx Sub-Task Group** brought forth DERF 001789 and updated guidance for the *SCRIPT Implementation Recommendations* document.
- The **X12 270/271 version 7030 Review Task Group** did not meet the past two quarters.
- The **XML Task Group** brought forth DERF 001785. The task group reviewed and provided recommendations on all submitted DERFs impacting the schema.
- The **SCRIPT Managed Updated Task Group** presented a proposal for an Expedited SCRIPT/Specialized ECL Process which was approved by the Work Group.

WG14 Long Term and Post Acute Care (LTPAC)

WG14 did not meet in August 2020. A recap of each task group activity is provided below.

Task Groups:

- The **LTPAC Billing Issues Task Group** continued working on questions received from the industry.
- The **Consultant Pharmacist Interoperability Task Group** did not meet the past two quarters but has plans for a pilot that incorporates the task group’s recommendations and applies FHIR® Resources to the Consult Note C-CDA.
- The **Long Term and Post-Acute Care ePrescribing Task Group** submitted DERFs 001760 and 001768.
 - The **Multi Communication Sub-Task Group** completed workflows 1 – 3 addressing current NCPDP solutions and workflows and where gaps in those workflows exist. They will continue work on additional workflows.
 - The **Recertification Sub-Task Group** brought forth a set of questions to be added to the *SCRIPT Implementation Recommendations* document which were approved.
- The **WG10 LTPAC Electronic Communication Synchronization Opportunity Review Task Group** had a presentation on the work being done by the Da Vinci project.
- The **WG14/WG10 Standardized Medication Profile Task Group** completed their gap analysis of the NCPDP and HL7 standards and reviewed the analysis. They determined HL7 FHIR® would be the best standard for the standardized medication profile. They began working on outlining the progress on this effort, including the gap analysis, and next steps to bring the work to the HL7 Pharmacy work group.
- The **WG11/WG14 RxFill Task Group** continued working on a DERF for enhancements to the RxFill message.

Work Group 16 Property and Casualty/Workers’ Compensation

Task Groups:

- The **P and C/WC Monitoring, Billing and Education Task Group** provided a presentation on legislative and regulatory updates for the following states: California, Florida, Montana and New York.
- The **Future Development Needs for P and C/WC Task Group** did not meet the past two quarters.

New Business:

- Disbandment of WG16
 - Status of Task Groups:
 - **P and C/WC Monitoring, Billing and Education Task Group** is moving under WG1.
 - **Future Development Needs for P and C/WC Task Group** is disbanded.

Work Group 18 Specialty Pharmacy

DERF Reviewed:

- DERF 001790 was approved.

Task Groups:

- The **Specialty Pharmacy Data Exchange Task Group** completed the 'Inventory' use case and submitted DERF 001790, Guidance and examples for an implementation of the X12 852 (Product Activity Report). The work group approved the DERF. The task group began to identify data elements for the 'Performance Metrics' use case. There was a discussion of a possible beta implementation of the Specialty Pharmacy Data Reporting Standard.
- The **Specialty Requirements for ePrescribing Task Group** continued working on a new Specialty Implementation Guide. The project scope statement for use of FHIR® for the Specialty transaction was approved by the HL7 work group. Task Group members attended the HL7 Connectathon in May to get feedback on the Specialty Implementation Guide as part of the HL7 balloting process.
- The **Stakeholder Outreach and Education Task Group** updated the Specialty page of the NCPDP website and reviewed a communication piece to manufacturers encouraging participation in WG18 task groups. The task group continues to monitor educational opportunities related to Specialty business.
- The **Benefit Coverage Identification Task Group** edited the pended NCPDP *Specialty Pharmacy Benefit Coverage Identification* White Paper to address feedback received at the February Work Group meeting and throughout the last two quarters. The work group approved the white paper.
- The **Patient Consent Task Group** documented the common types of authorization and consent from existing specialty pharmacy and DME forms. The task group decided separate transactions for patient consent is better than incorporating into SCRIPT NewRx. Frank McKinney of Point-of-Care Partners provided an overview and example of the FHIR® Consent Resource.
- The **Facilitating Access to Specialty Products Task Group** co-leads did not provide a task group recap report.

Other Reportables:

- **WG1 Expanded Dollar Fields Task Group, WG10 Identification of Social Determinants of Health Task Group, WG11 Prior Authorization Workflow-to-Transaction Task Group, WG11 REMS Workflow-to-Transaction Task Group and MC Real Time Prescription Benefit Standard Task Group:** Recaps for these task groups were provided in the WG18 download materials.

Work Group 45 External Standards Assessment, Harmonization and Implementation Guidance

WG45 did not meet in August 2020. A recap of each task group activity is provided below.

Task Groups:

- The **834/835 FAQ Task Group** did not meet the past two quarters.
- The **Document Revisions Task Group** did not meet the past two quarters.
- The **Pharmacy and/or Combination ID Card Task Group** did not meet the past two quarters.
- The **DSMO Task Group** received no DSMO requests for review. The task group is on hiatus until further notice.

MC Maintenance and Control

Ballot Adjudication:

- Ballot WGMC0008 - Enhancements to the Real-Time Prescription Benefit Standard Implementation Guide Version 10 is considered a valid ballot having received the required 60+% of Consensus Group

votes and 75%+ approval rating. No comments to the ballot were received. The ballot will be sent to NCPDP Board of Trustees for approval after a 30-day appeal period.

DERFs/ECLs: 28 new and 5 pended DERFs/ECLs were reviewed (see WG1, WG2, WG9, WG11 and WG18).

- DERF 001753/ECL 000321 was pended.
- DERF 001755 was pended.
- DERF 001757 was withdrawn by the submitter and replaced with DERF 001789.
- DERF 001760 was approved.
- DERF 001763 was withdrawn by the submitter.
- DERF 001768/ECL 000326 was approved.
- DERF 001769/ECL 000327 was approved.
- DERF 001770/ECL 000328 was approved.
- DERF 001771/ECL 000329 was approved as modified.
- DERF 001772/ECL 000330 was approved.
- DERF 001773 was approved.
- DERF 001774/ECL 000331 was pended.
- DERF 001775/ECL 000332 was approved.
- DERF 001776 was approved as modified.
- DERF 001777 was approved as modified.
- DERF 001778 was approved.
- DERF 001779 was pended.
- DERF 001780 was pended.
- DERF 001781 was approved.
- DERF 001782 was pended.
- DERF 001783 was approved.
- DERF 001784 was approved.
- DERF 001785 was approved.
- DERF 001786 was approved.
- DERF 001787 was approved.
- DERF 001788 was approved.
- DERF 001789 was approved.
- DERF 001790 was approved.
- DERF 001791 was approved with modifications.
- DERF 001792 was approved with modifications.
- DERF 001793 was approved.
- DERF 001794 was approved with modifications.
- DERF 001795/ECL 000333 was approved.

Old Business:

- Received updates on:
 - Board of Trustees
- Updates for the following were provided in the MC download materials:
 - HIPAA
 - SNIP Committee
 - DSMO Change Request System (CRS) Requests No. 1201, 1202, and 1208
 - Project 000055 Pharmacogenetic - Guided Therapy

Task Groups:

- The **Education/Legislation and Regulations Task Group** submitted comments to the FDA regarding *Food and Drug Administration 21 CFR Parts 1 and 251 [Docket No. FDA–2019–N–5711] RIN 0910–AI45 Importation of Prescription Drugs* and to the Office of the National Coordinator for Health Information Technology (ONC) regarding the *ONC Proposed 2020-2025 Federal Health IT Strategic Plan*.
- The **API Task Group** did not meet the past two quarters. The updated *Operating Rules Connectivity* Version 2.0 was published in April 2020. Since the work of the task group is complete, there was a request to disband the task group. The Work Group approved disbandment.
- The **Emergency Preparedness Task Group** completed the annual review of the *NCPDP Emergency Preparedness Information* document. Version 1.7 was published on an emergency basis on May 1, 2020 and incorporated information related to the COVID-19 pandemic. The task group sponsored national acceptance of a NCPDP Emergency Preparedness NDC for COVID 19 specimen collection at the pharmacy during a state of emergency in conjunction with WG2. Additional modifications were made to the *NCPDP Emergency Preparedness Information* in the second quarter and Version 1.8 was presented for Work Group approval. The Work Group approved Version 1.8.
- The **X12 TR3 Comment Consolidation Task Group** did not meet the past two quarters.
- The **ECL Task Group** did not meet the past two quarters. The Standardization Committee recommended disbandment of this task group and the Work Group approved.
- The **Real Time Prescription Benefit Standard Task Group** submitted four DERFs for enhancements to the Real Time Prescription Benefit (RTPB) Standard:
 - DERF 01791 – RTPB Deductible Fields
 - DERF 01792 – RTPB Estimated Combined Plan and Patient Savings
 - DERF 01793 – RTPB Imp Guide Restricted Prescriber
 - DERF 01794 – RTPB Standard Modifications for UPI

The task group began to explore a new use case (Cash Discount Program) for use of the RTPB Standard between a provider and a PBM/processor. The task group also received milestone updates from John Hopkins from their NCPDP Foundation sponsored pilot of the RTPB Standard.

- The **Consumer-Facing RTPB and Price Transparency Sub-Task Group** was created by the Real Time Prescription Benefit Standard Task Group in response to Project Development Form 000054 Consumer Facing Real Time Benefit Check. The sub-task group determined their name and scope statement which was approved by the parent task group. They also started to discuss the use cases for the Consumer Facing RTPB and price transparency transaction. Frank McKinney from Point-of-Care Partners provided a presentation about the HL7 Consumer Real-time Pharmacy Benefit Check FHIR® Implementation Guide.
- The **Gender Transition Task Group** created a DERF to request a new data element for “Sex Assigned at Birth.” The DERF needs additional work and will be submitted for November Work Group. The task group also worked on a FAQ document for use of the new Sex Assigned at Birth field.
- The **Harmonization Formation Task Group** did not meet the past two quarters. The Standardization Committee Chair presented an update on the Committee’s actions in response to the task group’s recommendations in February. There was a request to disband the task group and the Work Group approved.
- The **Digital Therapeutics Task Group** completed a gap analysis of the remaining Telecommunication and SCRIPT transactions and confirmed no additional data elements are needed for them to support the initial use case of the task group. The task group drafted the *Background and Guidance for Using the NCPDP Standards for a Digital Therapeutic Product* document to provide guidance on the use of NCPDP Standards for the ordering and fulfillment of Digital Therapeutic (DTx) products and services and submitted it for Work Group approval. The Work Group approved the paper.

- The **NDC Scarcity Task Group** is on hiatus and did not meet the past two quarters.
- The **Definition and Use of Quantity and Day Supply Task Group** developed a new definition for Days Supply (405-D5) and DaysSupply. The task group also drafted a FAQ with an accompanying table of examples and exceptions related to the new definition for Days Supply (405-D5). They also initiated the evaluation of quantity related data elements for the purpose of determining whether the name and definition of the data element reflects how it is being used and identifying any opportunities for sunsetting or consolidating quantity related fields.

New Business:

- The **MC 2D Barcode Implementation Task Group** was reactivated to update the outdated information in the NCPDP *GS1 DataMatrix* White Paper.
- A new task group, **Pharmacy Services Billing Task Group**, was formed for Work Group 1 to address how NCPDP real-time standards can be used to support direct patient care services offered by a pharmacy provider.
- A new task group, **F&B and RTPB Task Group**, was formed to determine if there needs to be synchronization in the timelines for adoption of the next versions of the Formulary & Benefit Standard and the Real Time Prescription Benefit Standard.